New blood thinner argatroban tested in heart stent patients

NCT ID NCT00508924

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three doses of argatroban, a blood thinner, in 140 patients undergoing elective heart stent procedures. It compared argatroban to the standard blood thinner heparin, both given with clopidogrel and aspirin. The goal was to see how well argatroban prevents blood clots and bleeding complications during and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Argatroban (a blood thinner) compared to heparin, both given with clopidogrel and aspirin
What this could lead to: If successful, argatroban could offer a safer or more effective blood-thinning option for patients undergoing heart stent procedures.
What could go wrong: This is an early phase 2 trial with only 140 participants, so results may not apply to all patients. Bleeding risks are a concern with any blood thinner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGINA, UNSTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGINA, UNSTABLE CORONARY ARTERY DISEASE

Contacts and locations

Locations

Study site

Aalst, Belgium
Study site

Bad Nauheim, Germany
Study site

Cologne, Germany
Study site

Dachau, Germany
Study site

Düren, Germany
Study site

Frankfurt, Germany
Study site

Halle, Germany
Study site

Mainz, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.